Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
-
Mersana Therapeutics to Present at Upcoming Investor Conferences
-
Mersana Therapeutics to Present at Upcoming Investor Conferences
-
Mersana Therapeutics to Present at Upcoming Investor Conferences
-
Mersana Therapeutics to Present at Upcoming Investor Conferences
-
Mersana Therapeutics to Present at Upcoming Investor Conferences
-
Mersana Therapeutics to Present at the Cowen 42nd Annual Health Care Conference
-
Mersana Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
-
Mersana Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
-
Mersana (MRSN) Defended at Cowen
-
Mersana Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Mersana Therapeutics (MRSN) Prices 8M Share Common Offering at $19/Sh
-
Mersana Therapeutics Announces Pricing of Public Offering of Common Stock
-
Mersana Therapeutics (MRNS) to Offer 5M Shares
-
Mersana Therapeutics Announces Proposed Public Offering of Common Stock
-
Mersana Therapeutics Raises $65 Million in Gross Proceeds Through its At-the-Market Facility
-
Mersana Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Updates
-
Mersana Therapeutics to Present at Upcoming Investor Conferences
-
Mersana Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates
-
Mersana Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates
-
Mersana Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference
-
Mersana Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference
-
Mersana Therapeutics (MRSN) Partial Clinical Hold on XMT-1522 is Disappointing - Cowen
-
Mersana Therapeutics to Present at Upcoming Investor Conferences
-
Cowen Starts Mersana (MRSN) at Outperform
-
Mersana Therapeutics (MRSN) IPO Opens Modestly Lower

